Inrebic (fedratinib) — Highmark
Myelofibrosis
Preferred products
- Jakafi (ruxolitinib)
Initial criteria
- age ≥ 18 years
- diagnosis of myelofibrosis that is intermediate-2 or high-risk
- if new start to therapy: baseline platelet count > 50 x 10^9/L AND therapeutic failure, contraindication, or intolerance to plan-preferred product Jakafi
Reauthorization criteria
- prescriber attests member has experienced a reduction in spleen size OR improvement in symptoms